Academic Journal
The astragaloside-brucea javanica oil nanoemulsion inhibiting the progression of oral squamous cell carcinoma through CDK1- HOXC10-MTFR2 pathway.
| Τίτλος: | The astragaloside-brucea javanica oil nanoemulsion inhibiting the progression of oral squamous cell carcinoma through CDK1- HOXC10-MTFR2 pathway. |
|---|---|
| Συγγραφείς: | Lai Y; Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Liu R; School of Stomatology, Nanchang University, Nanchang, Jiangxi Province 330006, China., Zhou L; Department of Otorhinolaryngology, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Wan Z; Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China; Department of Otorhinolaryngology, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Zhan J; Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Xiong M; Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Jiang L; Department of Oral and Maxillofacial Surgery, Key Laboratory of Oral Diseases of Traditional Chinese Medicine, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Wang W; Department of Oral and Maxillofacial Surgery, Key Laboratory of Oral Diseases of Traditional Chinese Medicine, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China., Shao Y; Department of Oral and Maxillofacial Surgery, Key Laboratory of Oral Diseases of Traditional Chinese Medicine, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province 330006, China. Electronic address: shaoyisen@jxutcm.edu.cn. |
| Πηγή: | Bioorganic chemistry [Bioorg Chem] 2026 Aug 15; Vol. 178, pp. 109983. Date of Electronic Publication: 2026 May 12. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: United States NLM ID: 1303703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2120 (Electronic) Linking ISSN: 00452068 NLM ISO Abbreviation: Bioorg Chem Subsets: MEDLINE |
| Imprint Name(s): | Publication: Amsterdam : Elsevier Original Publication: New York, London, Academic Press. |
| Ιατρικοί όροι (MeSH): | Saponins*/pharmacology , Saponins*/chemistry , Mouth Neoplasms*/drug therapy , Mouth Neoplasms*/pathology , Mouth Neoplasms*/metabolism , Plant Oils*/chemistry , Plant Oils*/pharmacology , Antineoplastic Agents, Phytogenic*/pharmacology , Antineoplastic Agents, Phytogenic*/chemistry , Antineoplastic Agents, Phytogenic*/isolation & purification, CDC2 Protein Kinase/metabolism ; CDC2 Protein Kinase/antagonists & inhibitors ; Cell Proliferation/drug effects ; Homeodomain Proteins/metabolism ; Homeodomain Proteins/antagonists & inhibitors ; Homeodomain Proteins/genetics ; Emulsions/chemistry ; Emulsions/pharmacology ; Humans ; Animals ; Mice ; Mice, Nude ; Dose-Response Relationship, Drug ; Mice, Inbred BALB C ; Drug Screening Assays, Antitumor ; Structure-Activity Relationship ; Molecular Structure |
| Περίληψη: | Objective: This study aimed to investigate whether Astragaloside-Brucea javanica oil nanoemulsion (AS/BJO-NEs) inhibits the malignant progression of oral squamous cell carcinoma (OSCC) and to further explore its potential regulatory mechanisms. Methods: Immunohistochemistry (IHC) was used to evaluate the expression of related pathway proteins in human OSCC and adjacent normal tissues. Stable OSCC cell lines with knockdown or overexpression of CDK1/HOXC10 were established. The effects of AS/BJO-NEs and the underlying mechanisms were assessed in vitro through colony formation, wound healing, and Transwell invasion assays, as well as RT-qPCR, western blot, chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays. An OSCC subcutaneous xenograft model in nude mice was constructed for in vivo validation using RT-qPCR, western blot, hematoxylin and eosin (H&E) staining, and IHC. Results: Analysis of clinical samples revealed upregulated expression of CDK1, P-EZH2, HOXC10, MTFR2, and N-cadherin, alongside downregulated expression of H3K27me3 and E-cadherin in OSCC tissues. In vitro experiments confirmed that AS/BJO-NEs downregulated CDK1 in a concentration-dependent manner, subsequently reducing the expression of P-EZH2, HOXC10, and MTFR2, increasing H3K27me3 levels, and inhibiting cell proliferation, migration, and invasion. H3K27me3 was enriched in the HOXC10 promoter region, and HOXC10 directly bound to and activated MTFR2 transcription. In vivo experiments demonstrated that AS/BJO-NEs effectively inhibited tumor growth, regulated molecules within this pathway and epithelial-mesenchymal transition (EMT) markers, whereas CDK1 overexpression counteracted these effects CONCLUSION: This study demonstrates that AS/BJO-NEs exert anti-OSCC effects by inhibiting CDK1, downregulating HOXC10, thereby reducing MTFR2 expression, and suppressing cell proliferation, migration, invasion, and the EMT process. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: AS/BJO-NEs; CDK1-HOXC10-MTFR2 pathway; Epithelial-mesenchymal transition; OSCC |
| Substance Nomenclature: | EC 2.7.11.22 (CDC2 Protein Kinase) 0 (Saponins) 0 (Homeodomain Proteins) EC 2.7.11.22 (CDK1 protein, human) 0 (HOXC10 protein, human) 0 (Emulsions) 0 (Plant Oils) 0 (Antineoplastic Agents, Phytogenic) |
| Entry Date(s): | Date Created: 20260514 Date Completed: 20260716 Latest Revision: 20260716 |
| Update Code: | 20260717 |
| DOI: | 10.1016/j.bioorg.2026.109983 |
| PMID: | 42134202 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1090-2120 |
|---|---|
| DOI: | 10.1016/j.bioorg.2026.109983 |